Clinical trials
Cholangitis clinical trials
Below are recruiting cholangitis clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06699121RecruitingPhase 2
Testing LB-P8 for people with primary sclerosing cholangitis
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Sacramento, CaliforniaAges 18–75 - NCT06443606RecruitingPhase 3
Bezafibrate for primary biliary cholangitis with incomplete UDCA response
This trial tests if adding bezafibrate (200 mg or 400 mg) to standard UDCA treatment can improve liver function in people with primary biliary cholangitis whose UDCA alone isn't working well enough.
ParisAges 18–80 - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06297993Recruiting
Global study following adults with PSC
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
Sacramento, CaliforniaAges 18–75 - NCT06197308RecruitingEarly Phase 1
Testing a mouth bacteria treatment for PSC
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
Minneapolis, MinnesotaAges 18–76 - NCT05835505RecruitingPhase 2
Detox medicine study for primary sclerosing cholangitis
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
Chestnut Hill, MassachusettsAges 18–75 - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT04753996Recruiting
Testing bile-based “mini-liver” samples in PSC and non-PSC groups
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
Rochester, MinnesotaAges 18–85 - NCT03445585Recruiting
Biobank study for primary sclerosing and primary biliary cholangitis
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
Rochester, MinnesotaAges 18–85 - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT03175471Recruiting
MRI study of blood-vessel and tissue signs in child liver disease
This trial uses MRI scans to look for “biomarkers,” which are measurable signs in the liver, to better understand autoimmune liver diseases in children and teens. It may help doctors track disease and improve care by finding imaging patterns linked to illness.
Cincinnati, OhioAges 6–23
Hear when a new Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangitis?
- Yes. Clin2 currently lists 60 recruiting cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.